進階篩選

Technical category
    • Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • The establishment of National Biobank Consortium of Taiwan (NBCT)

      Precision Health Ecosystem FutureTech The establishment of National Biobank Consortium of Taiwan (NBCT)

      This project will establish a National biobank consortium of Taiwan through the fund support from the government. The National Health Research Institutes will establish a Central Office for the collaboration works, which includes collecting the number of samples of the human biological database in each biobank that agreed to join the Consortium. All Alliance need to follow the same SOP for the collection processthe quality of the biosample. Adequateconsistent clinical data will also be established under the Information Security Management Treaty. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network.In line with the need of biotechnologypharmaceutical industries.